The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 26,617 | 24,230 |
| Stock-based compensation | 9,691 | 18,470 |
| Deferred taxes | 18,800 | -6,919 |
| Depreciation and amortization | 22,632 | 46,172 |
| Unrealized gain on investment in equity securities | 3,140 | -589 |
| Non-cash operating lease expense | 358 | 846 |
| Non-cash interest | 340 | 665 |
| Contingent consideration fair value adjustment | -14,470 | -10,815 |
| Loss (gain) on disposal of assets | -295 | 0 |
| Loss on debt extinguishment | 0 | - |
| Amortization of inventory step up | 0 | - |
| Asset impairment charges | 767 | - |
| Accounts receivable, net | 26,965 | 3,709 |
| Inventories | 8,160 | 1,533 |
| Prepaid expenses and other assets | 6,454 | -5,890 |
| Accounts payable | 13,766 | 8,625 |
| Accrued royalties | 15,217 | 13,404 |
| Income taxes | -12,548 | -3,455 |
| Accrued government rebates | 4,166 | 14,152 |
| Returned goods reserve | 1,322 | 9,409 |
| Accrued expenses, accrued compensation, and other | 1,821 | -5,218 |
| Net cash and cash equivalents provided by operating activities | 44,055 | 110,803 |
| Acquisition of alimera, net of cash acquired | 0 | - |
| Acquisition of product rights, intangible assets, and other related assets | 60 | 20,267 |
| Acquisition of property and equipment, net | 6,103 | 6,488 |
| Proceeds from the sale of building | 0 | 0 |
| Net cash and cash equivalents used in investing activities | -6,163 | -26,755 |
| Proceeds from convertible notes | 0 | - |
| Proceeds from term loan | 0 | - |
| Purchase of capped call transaction | 0 | - |
| Repayment on borrowings under credit agreement | 0 | - |
| Debt issuance costs | 0 | - |
| Principal payments on borrowings | 2,031 | 4,062 |
| Series a convertible preferred stock dividends paid | 344 | 813 |
| Proceeds from stock option exercises and espp purchases | 9,790 | 3,776 |
| Treasury stock purchases for restricted stock vests | 1,044 | 10,554 |
| Payments on contingent consideration | 26 | 0 |
| Payment of accrued licensor payments | 0 | - |
| Net cash and cash equivalents (used in) provided by financing activities | 6,345 | -11,653 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 576 | 544 |
| Net change in cash, cash equivalents, and restricted cash | 44,813 | 72,939 |
| Cash and cash equivalents at beginning of period | 144,894 | - |
| Cash and cash equivalents at end of period | 262,646 | - |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)